adx-914
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 8, 2020 (NCT04485481)
Timeline
Indications
Mechanism of action
- Interleukin-7INHIBITOR
Interleukin-7 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06018428 | Phase 2 | Aug 28, 2023 | Innovaderm, Q32 Bio Inc. |
| NCT05509023 | Phase 2 | Sep 30, 2022 | Q32 Bio Inc. |
| NCT04485481 | Phase 1 | Sep 8, 2020 | Q32 Bio Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Q32 Bio Inc. | For profit | 3 | 3 | 2 | 2020 |
| Innovaderm | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1